Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
Executive Summary
Pfizer doesn't exactly do things by halves. Two years after pulling off the sector's biggest merger, it now appears to be carrying out the largest-scale – and most ambitious – academic tie-up yet.
You may also be interested in...
Mount Sinai Taps Smith For New Effort In Entrepreneurship
Managing Partner at Ascent Biomedical Ventures Geoffrey Smith recently began a new role at Mount Sinai Medical School that is helping academics translate their knowledge into real-world commercial opportunities.
Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.